Press Dispensary - 19 September 2005 - Bio Life Technical (http://www.biolifetechnical.com), a venture which employs renowned researchers from the fields of nanotechnology and personalised healthcare - such as Professor Chris Toumazou and Professor Sir Magdi Yacoub of Imperial College, London - is launching in London, UK. The company will provide independent technical due diligence services to world-wide investors.

Bio Life Technical is structured to aid venture capital groups, investment banks, business angels and institutional investors by providing a single point of contact and managing the technical due diligence reporting process on behalf of prospective investor clients. This will save time, resources and, therefore, money for the investment community.

Professor Chris Toumazou comments: ‘Technical due diligence and new medical technologies bring together different scientific disciplines that frequently need ‘cross-examination' by different experts. However, venture capital firms, early stage investors, investment banks and market research agencies do not generally have access to a multi-disciplinary network of scientific experts who can analyse their technology prospects at a high level.'

He adds: ‘This is where Bio Life Technical comes in - providing technical due diligence by experts working for the top institutes who will give a more thorough scientific evaluation of the emergent technologies concerned.'

Bio Life Technical can estimate a quantitative commercial value for a device, even at pre-development stage, without relying on the usual financial inputs. Aiden Williamson, a partner in Bio Life Technical, says: ‘Our service will give investors a clear edge when it comes to the evaluation of investment opportunities.'

By specialising in nanotechnology and personalised healthcare, Bio Life Technical is focusing on areas of high contemporary and future importance to the investment and financial community, industry, and scientific and healthcare organisations. Each of the technologies could cause significant and, in some cases, disruptive change in the status quo and growth prospects of most technology-dependent business sectors. For this reason, Bio Life Technical retains a cross-disciplinary approach, ensuring a comprehensive reporting structure.

Bio Life Technical manages the entire technical due diligence process, independently, on behalf of investors. The company draws upon advisors from internationally respected institutions such as Imperial College's Institute of Biomedical Engineering, Massachusetts Institute of Technology, Glasgow University and Oxford University.

Notes for editors
Bio Life Technical LLP provides independent technical due diligence services to the investment community. The company employs 14 researchers who work within nanotechnology and personalised healthcare. It is based in London, UK.

For more information, please contact:
Paul Constant Phone: + 44 (0) 20 7067 4320
Email: paul.constant@biolifetechnical.com
Site: www.biolifetechnical.com